Grid Oasis
S&P 500NASDAQ 100Dow JonesRussell 2000All StocksSectors & Industries

INCY

+ Watchlist+ Portfolio

Incyte Corp.

Regulated industryPhysical productsTags from an AI model reading the company description.
GridBrain

GridBrain — Sign in

GridSentinel

GridSentinel — Sign in

GridAegis

GridAegis — Sign in

Key Metrics

Previous Close
$119.09
52-Week Range
$89.25 – $132.60
Market Cap
$24.01B
P/E (TTM)
60.10
EPS (TTM)
1.96
Dividend Yield
0.00%
Advanced Metrics
Price/Book
4.26
PEG Ratio
10.82
Return on Equity
7.84%
Return on Assets
17.78%
Gross Margin
56.02%
Operating Margin
32.22%
Profit Margin
6.71%
Current Ratio
3.84
Debt/Equity
0.01
Total Debt
$37.41M
Free Cash Flow
$1.29B
Revenue Growth
14.00%
Earnings Growth
—
Enterprise Value
$20.19B

Market Snapshot

About

Incyte Corp. is a biopharmaceutical company focused on discovering, developing, and commercializing proprietary therapeutics for serious unmet medical needs. The company's marketed products include Jakafi for myelofibrosis and polycythemia vera, Pemazyre for cholangiocarcinoma, and Opzelura for atopic dermatitis and vitiligo. Incyte maintains a diverse pipeline of oncology and inflammation programs built around novel mechanisms including JAK inhibitors, FGFR inhibitors, and immuno-oncology approaches. The company combines internal drug discovery expertise with strategic collaborations to advance multiple therapeutic candidates across various disease areas.